[Download] "Evaluation of 143 Cases of Immune Thrombocytopenic Purpura with Regards to Clinical Course and Response to Treatment/Immun Trombositopenik Purpurali 143 Olgunun Klinik Seyir Ve Tedavi Cevabi Acisindan Degerlendirilmesi (Original Article) (Report)" by The Eurasian Journal of Medicine * eBook PDF Kindle ePub Free

Evaluation of 143 Cases of Immune Thrombocytopenic Purpura with Regards to Clinical Course and Response to Treatment/Immun Trombositopenik Purpurali 143 Olgunun Klinik Seyir Ve Tedavi Cevabi Acisindan Degerlendirilmesi (Original Article) (Report)

📘 Read Now 📥 Download

eBook details

Title: Evaluation of 143 Cases of Immune Thrombocytopenic Purpura with Regards to Clinical Course and Response to Treatment/Immun Trombositopenik Purpurali 143 Olgunun Klinik Seyir Ve Tedavi Cevabi Acisindan Degerlendirilmesi (Original Article) (Report)
Author : The Eurasian Journal of Medicine
Release Date : January 01, 2010
Genre: Health & Fitness,Books,Health, Mind & Body,
Pages : * pages
Size : 256 KB

Description

Introduction Immune thrombocytopenic purpura (ITP) is also known as idiopathic thrombocytopenic purpura [1]. No specific criteria are available for the diagnosis of ITP. ITP can be diagnosed after the exclusion of other diseases causing thrombocytopenia. Therefore, ITP is currently described as a primary immune thrombocytopenia [2, 3]. The clinical course of ITP is usually chronic in adults. In cases of chronic ITP, serious bleeding is not expected even with significant thrombocytopenia. The mortality rate due to bleeding secondary to ITP is less than 1% [4]. Corticosteroids are given as the first line of therapy in ITP cases with serious thrombocytopenia. Splenectomy is the standard care for cases that are non-responsive to corticosteroids. The rate of complete remission is 66% [5]. No consensus is currently available regarding the appropriate treatment of patients with serious thrombocytopenia who require treatment following the splenectomy [6]. Various post-splenectomy treatments have been administered to refractory patients. Azathioprine, vinka alkaloids, danazol, cyclophosphamide, high dose dexamethasone, rituximab, interferon, and cyclosporine have been used. The treatment of chronic refractory ITP is difficult because response to treatment is variable. Treatment-related serious side effects may be observed [7]. Thrombopoietin (TPO) receptor antagonists and anti-CD20 monoclonal antibodies are new treatment approaches with different mechanisms of action [8, 9].